Motley Fool6d agobullish
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3127last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
StockStory6d agoneutral
5 must-read analyst questions from Bristol-Myers Squibb’s Q3 earnings callGuruFocus.com6d agoneutral
What Invesco S&P Ultra Dividend Revenue ETF (RDIV) Bought: Chevron Leads on Oct. 29Simply Wall St.8d agobullish
What Bristol Myers Squibb Stock's Earnings Beat Means For ShareholdersSimply Wall St.8d agoneutral
Bristol Myers Squibb (BMY) Reports Positive Phase 2 Pumitamig Lung Cancer DataBarrons.com9d agoneutral
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling StockMT Newswires9d agoneutral
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $61 From $6324/7 Wall St.9d agoneutral
Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe?Pharmaceutical Technology9d agobullish
Eli Lilly’s tirzepatide outperforms big pharma companies in Q324/7 Wall St.38d agobullish
5 High-Yield Dividends With Ex-Dates Days Away: Buy Before the Window ClosesInvestor's Business Daily39d agoneutral
This Pharma Giant Has The Right Medicine For Income Investors24/7 Wall St.39d agoneutral
Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow MetricSimply Wall St.40d agoneutral
How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) InvestorsMotley Fool40d agobullish
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?Investor's Business Daily40d agoneutral
AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, MerckSimply Wall St.40d agoneutral
Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 TrialBarrons.com40d agoneutral
Inside the AstraZeneca Deal That Could Send Summit Therapeutics Stock Up 162%